Skip to main content
OpenTrials
Completed

NCT Number: NCT04519814

Safety and Effectiveness of VISULAS Green Selective Laser Trabeculoplasty (SLT)

An interventional, open, prospective, multi-center pre-market clinical investigation according to §§20-23a Medizinproduktegesetz (MPG, medical devices act), in which a total of 40 eyes of 40 consecutive patients at up to five (5) clinical sites will be enrolled, treated with the VISULAS green with option CSLT, and followed for a three months period.

The primary objective of this clinical investigation is to evaluate safety and effectiveness of SLT with the VISULAS green laser with option CSLT.

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Klinik und Poliklinik für Augenheilkunde, TU Dresden, Dresden, Germany

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and females at least 22 years of age or older, primary open-angle glaucoma (HPG + NPG), who did not reach target pressure .
  • IOP with or without medications ≥17 mmHg in the study eye
  • Chamber angle Shaffer 3 and 4
  • Patients must be legally competent and able to give consent and must have read, understood and signed patient information leaflet and consent to undergo SLT in one eye
  • Patients are willing and able to return for follow-up examinations
  • In the opinion of the investigator, the patient will be compliant and have a high probability of completing the clinical investigation and all required procedures

Exclusion criteria

  • Corneal disease or pathology in a way that distortion of laser light in the study eye can be expected or that precludes stabilization of the cornea by the contact glass, visibility of the trabecular meshwork or transmission of laser wavelength
  • Strong clouding of the anterior ocular media (e.g. the lens due to dense cataract) and the vitreous body (e.g. due to strong vitreous hemorrhage) in either eye
  • Deep orbits and/or narrow palpebral fissures
  • Corneal or conjunctival abnormality precluding contact lens adaptation in either eye
  • History of Amblyopia in either eye
  • Any contraindications to SLT in study eye.
  • Any kind of planned ocular surgeries during the next 3 months (for example, cataract surgery) in either eye
  • Previous intraocular or corneal surgery of any kind (except cataract surgery longer than three months prior to the clinical investigation), including surgical glaucoma intervention in study eye before the clinical investigation.
  • Signs of Fuchs' Dystrophy (e.g. corneal endothelial guttata) in either eye
  • Active or history of Uveitis in either eye
  • Congenital glaucoma in either eye
  • Diabetic retinopathy or branch retinal vein occlusion with the risk to develop neovascularizations in either eye
  • Heavily pigmented trabecular meshwork due to pseudoexfoliation syndrome or pigment dispersion glaucoma in either eye
  • Degenerative disorders of the central nervous system if it prevents proper compliance or the ability to undergo the tests in the clinical investigation (e.g. Parkinson Disease, Alzheimer Disease, or other forms of dementia)
  • History of or has a current, clinically significant major psychiatric disorder (e.g., major depressive disorder, psychosis, schizophrenia)
  • Patients who are pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control.
  • Enrollment in another drug or device study within the prior 3 months

Treatment and study plan

selective laser trabeculoplasty (SLT)

Procedure

Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.

Primary outcomes

  1. mean absolute change in intraocular pressure (IOP) compared to baseline at month 1

    Time frame: one (1) month

    The endpoint is the mean change in IOP (Absolute value, mmHg) of the study cohort compared to baseline at month 1

Secondary outcomes

  1. mean relative change in intraocular pressure (IOP) compared to baseline at month 1

    Time frame: one (1) month

    The endpoint is the mean change in IOP (relative value, %) of the study cohort compared to baseline at month 1

  2. mean absolute change in intraocular pressure (IOP) compared to baseline at month 3

    Time frame: three (3) months

    The endpoint is the mean change in IOP (Absolute value, mmHg) of the study cohort compared to baseline at month 3

  3. mean relative change in intraocular pressure (IOP) compared to baseline at month 3

    Time frame: three (3) months

    The endpoint is the mean change in IOP (relative value, %) of the study cohort compared to baseline at month 3

Other outcomes

  1. rate of patients achieving >0 to <10% IOP reduction from baseline

    Time frame: three (3) month

    The following exploratory endpoint will be determined additionally:

    • rate of patients achieving >0 to <10% IOP reduction from baseline at 1 and 3 months
  2. rate of patients achieving 10% to <20% IOP reduction from baseline

    Time frame: three (3) month

    The following exploratory endpoint will be determined additionally:

    • rate of patients achieving 10% to <20% IOP reduction from baseline at 1 and 3 months
  3. rate of patients achieving ≥20% IOP reduction from baseline

    Time frame: three (3) month

    The following exploratory endpoints will be determined additionally:

    • rate of patients achieving ≥20% IOP reduction from baseline at 1 and 3 months.
  4. Post-operative intraocular pressure (IOP) in mmHg

    Time frame: one (1) day

    Outcome Parameters Safety: Post-operative intraocular pressure (IOP) in mmHg: 1h, 1d

  5. Rate of intraoperative Adverse Device Effects

    Time frame: one (1) day

    Outcome Parameters Safety: Rate of intraoperative Adverse Device Effects

  6. Rate of Adverse Device Effects and Device Deficiencies

    Time frame: three (3) month

    Outcome Parameters Safety: Rate of Adverse Device Effects and Device Deficiencies over the entire course of the investigation

  7. Rate of Adverse Events and Severe Adverse Events

    Time frame: three (3) month

    Outcome Parameters Safety: Rate of Adverse Events and Severe Adverse Events over the entire course of the clinical investigation

Sponsors and collaborators

Lead sponsor

Carl Zeiss Meditec AG

Industry

Registry information

Official study title

A Prospective, Multicenter Clinical Investigation to Evaluate Safety and Effectiveness of VISULAS Green Selective Laser Trabeculoplasty (SLT)

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
Aug 20, 2020
Registry last updated
Dec 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.